CANNABIS SCIENCE Forum: Community User: isa

Zauberer, Schau dort mal die Aktie an und schreibe mir was du davon hälst, A0QZLM

Brauch erst einen starke Kaffee ;-)

Zauberer du weißt Bescheid

Hoffentlich aufwärts und nicht gleich wieder runter. Bin echt gespannt.

Dann kanns ja weiter aufwärts gehen

Danke

Bitte

Auf deutsch bitte

Gestern gab es Neuigkeiten von CS. IRVINE, CA -- (Marketwired) -- 01/25/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces its California distributors have sold out of Cannabis Science's recently released CBIS Metered Dose Inhalers (MDI) in an initial test market run in the State of California. Cannabis Science is excited to report it has increased production of the inhalers to meet this new consumer demand. Cannabis Science's CEO, Mr. Raymond C. Dabney, stated, "We did not expect demand for our Inhaler to increase so rapidly. While it was not a particularly large initial test batch, there were certainly enough indicators in the pilot program that point to a great success considering the application and target market. Consequently, we have substantially increased production with our current manufacturer and are identifying and implementing key manufacturing and distribution expansions to ensure we meet the growing demand for the CBIS MDI Inhaler." As previously noted, the California market is stated to be the most populous state in the US and has the world's sixth-largest economy with a gross domestic product of about $2.5 trillion. The potential revenue stream for Cannabis Science should increase dramatically with the additions to the legal Cannabis market sectors. The city of Los Angeles surrounds West Hollywood, and the neighboring districts include Hollywood, Sunset Strip, Beverly Center, and Wilshire, some of the largest demographic addressable markets in the Los Angeles area, which explains the high demand for CBIS products. The Company is also exploring additional observational studies using the CBIS MDI's potential to alleviate breathing problems and pain associated with lung cancer and other target ailments. Given the demand for our inhaler, "Cannabis Science has evaluated the potential for a Dry-powder Inhaler (DPI) as a long-term therapy of these diseases and we've decided to go forward with the development of this medication for our customers. A DPI is a device that delivers medication to the lungs in the form of a dry powder. DPI's are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema, and COPD. With the development of a CBIS DPI, we will continue to strive to meet the growing needs of our consumers by offering more choices using the strength of cannabinoids for critical ailment treatments," stated Dr. Allen Herman, Chief Medical Officer (CMO), Cannabis Science Inc. The CBIS MDI device can offer the ingestion of the medication in a finer particle mist than the Nebulizer version which can be quickly absorbed by the Lungs and spread into the Blood Stream for quicker response time. Rescue Inhalers cannot replace Nebulizer Medications but the portability of these devices gives the Asthma/COPD sufferer freedom to be out enjoying life knowing their medication is at hand if needed. How Cannabinoids may help Asthma/COPD: Cannabinoids relieve inflammation Cannabinoids are anti-microbial Cannabinoids support / modulate the immune system and its response to infection and disease Cannabinoids are expectorants Cannabinoids are analgesic (pain relief) Cannabinoid medicine has little to no side effects Look for these New CBIS Formulations in Production: The CBIS Suppository is used for pain relief and relaxation. This product has moderate dosing, increased bioavailability, a low psychoactive effect, and offers a broad spectrum of medical effects due to its ratio of Cannabidiol (CBD) and Tetrahydrocannabinol (THC). Product ingredients include organic cocoa butter and organic coconut oil infused with the flowers of two different CBD varieties. Cannabis Science's Wholesome Honey Oil is used for improved sleep, cough, cold and flu relief, pain relief, anxiety and stress relief, reduction of ulcers and other gastrointestinal disorders, and as an antibacterial. This product's ingredients include raw, organic honey infused with full extract cannabis oil. Cannabis Science Enhanced Healing Balm incorporates a special skin regenerating formula and is used as an anti-inflammatory and anti-bacterial. This product is also used for topical pain relief and discomfort associated with menstrual cramps, arthritis, major aches, pain, dry skin, tension headaches, and more. Our Healing Balm is available in THC, CBD, or Hempseed varieties.

Wurde bei General Cannabis gepostet: Marijuana legalization supporters, and other civil rights advocates, have been understandably glued to the attorney general confirmation hearings for Alabama Senator Jeff Sessions, but the upcoming nomination to head the Food and Drug Administration (FDA) could soon take center stage. The FDA has been unwilling to consider marijuana itself medicine, even though it has approved the use of three marijuana-based medicines. Marijuana law reform activists are encouraged by the possibility of Jim O’Neill being tapped to lead the FDA, as attn.com reported: “Seeing Jim’s name floated gives us reason for a little optimism in the midst of so many old school drug warriors being tapped for other key posts,” Marijuana Majority founder Tom Angell told ATTN:. “I feel confident that if he becomes the next FDA commissioner, we will be in very good position to finally reschedule marijuana.” Mike Liszewski, the director of government affairs at Americans for Safe Access, agreed. He told ATTN: that O’Neill’s prospective nomination “could bring about significant changes to medical cannabis policy” and “potentially address the regulations that have prevented medical cannabis research.” “Such reforms could ultimately lead to cannabis being removed from Schedule I of the Controlled Substances Act,” Liszewski said. “However, whatever progress on cannabis at FDA under the Trump Administration should not be used as justification for cracking down on state medical cannabis programs, as there are more than 2 million patients who rely on these programs for safe and legal access to their medicine.” Jim O’Neill, who has close ties with fellow legalization supporter Peter Thiel (who served on Trump’s transition team), served as a founding member of the Coalition for Cannabis Policy Reform. O’Neill could provide a sensible voice on cannabis within the Donald Trump Administration. While we’ll continue to read through the tea leaves, trying to determine what Donald Trump’s federal cannabis policy will be, it is clear that marijuana legalizers must remain vigilant throughout the Trump Administration, particularly with the White House’s prioritization of law-and-order policies, and especially if Jeff Sessions is indeed confirmed as the next attorney general. The nomination of a marijuana legalizer could be just what the cannabis community needs to protect the gains we’ve worked so hard to achieve.

Dinkelsbühl

Im Sinne des Wortes sogar... Lol

Jap... Hier ist es auch sehr spannend...

Meinte Erdingen..?

Gastro wo... Erringen zufällig.?

Servus Jap... Bin hier bisschen investiert...